KMT Pharma

KMT Pharma (K.M.T. Pharma Ltd.) is an Israeli pharmaceutical company that operates as both a major distributor of healthcare products and a developer of novel therapeutics. Founded in 1994, the company's research and development efforts have historically focused on metabolic diseases, particularly the development of small molecule G protein-coupled receptor 119 (GPR119) agonists for the treatment of type 2 diabetes and obesity. KMT Pharma's distribution arm provides a wide range of services including marketing, sales, and logistics for international pharmaceutical companies in the Israeli market. While its R&D pipeline includes candidates like KMT-1107, the company is widely recognized for its established presence in the Israeli pharmaceutical supply chain. The company is headquartered in Herzliya, Israel, and continues to serve as a key player in the regional healthcare sector.